1 April 2016 - NHS England will release crucial funding for HIV therapy Rezolsta, its once-daily, fixed-dose combination of darunavir ethanolate and the ‘pharmacoenhancer’ cobicistat.

The drug is indicated for use in combination with other antiretroviral medications for treating adults with human immunodeficiency virus-1 (HIV-1) whose virus does not carry darunavir resistance-associated mutations.

This decision means that, across England, clinicians will be able to routinely prescribe darunavir - the UK's most prescribed protease inhibitor - combined with a ‘booster’ in a single pill to adults living with HIV-1.

“By funding treatment, NHS England is making available a treatment option for individuals who require darunavir to effectively control the HIV, but who would potentially also benefit from the convenience of fewer tablets to support their adherence to treatment,” noted Rozlyn Bekker, medical director of Janssen UK.

For more details, go to: http://www.pharmatimes.com/Article/16-04-01/NHS_England_funds_Janssen_s_HIV_pill_Rezolsta.aspx